ATE547524T1 - Neuartige expressionsvektoren mit zusätzlichen molekül-ligandgenen und ihre verwendung zur immunmodulation und zur behandlung von malignomen und autoimmunkrankheiten - Google Patents

Neuartige expressionsvektoren mit zusätzlichen molekül-ligandgenen und ihre verwendung zur immunmodulation und zur behandlung von malignomen und autoimmunkrankheiten

Info

Publication number: ATE547524T1
Authority: AT; Austria
Prior art keywords: treatment; autoimmune diseases; malignoms; expression vectors; molecule ligand
Prior art date: 1996-12-09

Application number

AT09164341T

Other languages

English (en)

Inventor

Thomas J Kipps

Sanjai Sharma

Mark Cantwell

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-09

Filing date

1997-12-08

Publication date

2012-03-15

1997-12-08 Application filed by Univ California filed Critical Univ California

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE547524T1 publication Critical patent/ATE547524T1/de

Links

239000003446 ligand Substances 0.000 title abstract 3
108090000623 proteins and genes Proteins 0.000 title abstract 3
238000011282 treatment Methods 0.000 title abstract 3
208000023275 Autoimmune disease Diseases 0.000 title abstract 2
239000013604 expression vector Substances 0.000 title 1
230000008102 immune modulation Effects 0.000 title 1
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002519 immonomodulatory effect Effects 0.000 abstract 1
230000036210 malignancy Effects 0.000 abstract 1
230000006641 stabilisation Effects 0.000 abstract 1
238000011105 stabilization Methods 0.000 abstract 1
102000003390 tumor necrosis factor Human genes 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Immunology (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

AT09164341T 1996-12-09 1997-12-08 Neuartige expressionsvektoren mit zusätzlichen molekül-ligandgenen und ihre verwendung zur immunmodulation und zur behandlung von malignomen und autoimmunkrankheiten ATE547524T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3214596P	1996-12-09	1996-12-09
US08/982,272 US7070771B1 (en)	1996-12-09	1997-12-01	Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells

Publications (1)

Publication Number	Publication Date
ATE547524T1 true ATE547524T1 (de)	2012-03-15

Family

ID=26708033

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT09164341T ATE547524T1 (de)	1996-12-09	1997-12-08	Neuartige expressionsvektoren mit zusätzlichen molekül-ligandgenen und ihre verwendung zur immunmodulation und zur behandlung von malignomen und autoimmunkrankheiten
AT97954089T ATE420956T1 (de)	1996-12-09	1997-12-08	Expressionsvektoren die gene enthalten für akzessorische molekül-liganden und deren verwendung zur immunomodulation und behandlung von bösartigen tumoren und autoimmunkrankheiten

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT97954089T ATE420956T1 (de)	1996-12-09	1997-12-08	Expressionsvektoren die gene enthalten für akzessorische molekül-liganden und deren verwendung zur immunomodulation und behandlung von bösartigen tumoren und autoimmunkrankheiten

Country Status (16)

Country	Link
US (3)	US7070771B1 (de)
EP (4)	EP1806360A3 (de)
JP (1)	JP4015201B2 (de)
CN (1)	CN1221662C (de)
AT (2)	ATE547524T1 (de)
AU (1)	AU5795798A (de)
BR (1)	BR9714004A (de)
CA (2)	CA2274498C (de)
DE (1)	DE69739220D1 (de)
DK (1)	DK0948614T3 (de)
ES (1)	ES2321246T3 (de)
IL (3)	IL130247A0 (de)
NO (2)	NO327411B1 (de)
NZ (1)	NZ336092A (de)
PT (1)	PT948614E (de)
WO (1)	WO1998026061A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7070771B1 (en) *	1996-12-09	2006-07-04	Regents Of The University Of California	Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1173589A1 (de) *	1999-04-16	2002-01-23	F. Hoffmann-La Roche Ag	Nukleotidensäure kodierend für cd40/cd40l chimerische polypeptiden , verfahren fur deren herstellung and anwendung davon
GB9917180D0 (en) *	1999-07-23	1999-09-22	Univ Sheffield	Cell surface receptor
GB0025307D0 (en) *	2000-10-16	2000-11-29	Celltech Chiroscience Ltd	Biological products
WO2002036769A2 (en) *	2000-10-31	2002-05-10	F. Hoffmann-La Roche Ag	Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7786282B2 (en) *	2001-12-06	2010-08-31	The Regents Of The University Of California	Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
WO2003070271A2 (en) *	2002-02-25	2003-08-28	Isis Innovation Limted	Novel complexes for inducing an immune response
US7495090B2 (en) *	2002-05-23	2009-02-24	The Regents Of The University Of California	Nucleic acids encoding chimeric CD154 polypeptides
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
US20130266551A1 (en)	2003-11-05	2013-10-10	St. Jude Children's Research Hospital, Inc.	Chimeric receptors with 4-1bb stimulatory signaling domain
US20080044393A1 (en) *	2004-07-16	2008-02-21	White Robert L	Retinal dystrophin transgene and methods of use thereof
WO2008109825A2 (en) *	2007-03-08	2008-09-12	Mayo Foundation For Medical Education And Research	Inducing immune-mediated tumor cell death
US20100050276A1 (en) *	2008-08-22	2010-02-25	Brown University	Transgenic non-human animal models of apoptosis-mediated conditions
EP2788021B1 (de)	2011-12-09	2017-01-18	Bavarian Nordic A/S	Pockenvirus-vektor zur expression von bakteriellen antigen, welche mit tetanus toxin fragment c verbunden sind
CA2888193A1 (en) *	2012-10-17	2014-04-24	Eyal Breitbart	Treatment methods using adenovirus
US20170173180A1 (en) *	2014-03-27	2017-06-22	The Regents Of The University Of Michigan	Cancer immunotherapy compositions and methods
JP6694875B2 (ja)	2014-05-15	2020-05-20	ナショナルユニヴァーシティオブシンガポール	改変ナチュラルキラー細胞及びその使用
CN105567679B (zh) *	2014-10-10	2019-07-05	深圳市北科生物科技有限公司	可分泌型trail蛋白构建物和表达载体
US20180244750A1 (en)	2015-11-02	2018-08-30	Memgen, Llc	Methods for treatment of cancer
US11298420B2 (en)	2016-12-21	2022-04-12	Memgen, Llc	Armed oncolytic viruses
KR102660336B1 (ko)	2017-03-27	2024-04-26	내셔널 유니버시티 오브 싱가포르	절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
WO2018191369A1 (en)	2017-04-12	2018-10-18	Memgen, Llc	Methods of cd40 and toll like receptor immune activation
US12258381B2 (en)	2018-02-09	2025-03-25	National University Of Singapore	Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh)	2018-04-02	2024-04-26	新加坡国立大学	用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
CN112601758A (zh)	2018-08-29	2021-04-02	新加坡国立大学	特异性刺激经基因修饰免疫细胞的存活和扩增的方法
SG11202109057XA (en)	2019-03-05	2021-09-29	Nkarta Inc	Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112725379B (zh) *	2021-01-27	2024-08-13	上海南方模式生物科技股份有限公司	人源化cd40基因改造动物模型的构建方法及应用
US11585330B1 (en) *	2021-09-29	2023-02-21	Halliburton Energy Services, Inc.	Flow control for geothermal well

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE107362T1 (de)	1986-06-20	1994-07-15	Dainippon Pharmaceutical Co	Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns.
WO1988009343A1 (fr)	1987-05-29	1988-12-01	Sagami Chemical Research Center	Proteine fusionnee contenant une lymphotoxine
ATE148992T1 (de)	1989-08-16	1997-03-15	Chiron Corp	Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
US5519119A (en)	1990-09-21	1996-05-21	Ishihara Sangyo Kaisha Ltd.	Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en)	1990-11-21	1992-05-22	Walter Fiers	Tnf-muteins
ES2227513T5 (es)	1991-10-25	2009-04-01	Immunex Corporation	Citoquina novedosa.
CA2133326C (en)	1992-03-30	2005-03-01	Craig A. Smith	Fusion proteins comprising tumor necrosis factor receptor
SK376492A3 (en)	1992-04-02	1995-06-07	Hoffmann La Roche	Tnf - muteins and method of their production
EP0615451B1 (de)	1992-05-26	2005-12-07	Immunex Corporation	Neue zytokine die cd30 binden
AU5098493A (en)	1992-08-21	1994-03-15	Schering Corporation	Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0656947A1 (de)	1992-08-21	1995-06-14	Schering Corporation	Menschliches interleukin-13
US5540926A (en)	1992-09-04	1996-07-30	Bristol-Myers Squibb Company	Soluble and its use in B cell stimulation
US5573924A (en)	1992-09-08	1996-11-12	Immunex Corporation	CD27 ligand
US5565321A (en)	1993-01-22	1996-10-15	Immunex Corporation	Detection of mutations in a CD40 ligand gene
ES2211876T3 (es)	1993-01-22	2004-07-16	Immunex Corporation	Deteccion y tratamiento de mutaciones en un gel del ligando de cd40.
US5830463A (en)	1993-07-07	1998-11-03	University Technology Corporation	Yeast-based delivery vehicles
US5861310A (en) *	1993-11-03	1999-01-19	Dana-Farber Cancer Institute	Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja)	1993-11-10	1996-05-21	Mochida Pharmaceut Co Ltd	Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) *	1993-11-24	1995-06-13	Australian National University, The	Treatment of viral disease with cd40l peptide
CA2179196A1 (en)	1993-12-23	1995-06-29	Richard J. Armitage	Method of preventing or treating disease characterized by neoplastic cells expressing cd40
WO1995018819A1 (en)	1994-01-07	1995-07-13	Immunex Corporation	Ligand that binds fas antigen
CA2188165C (en)	1994-04-28	2007-08-28	Marilyn Kehry	Methods for proliferating and differentiating b cells, and uses thereof
US5606023A (en)	1994-05-24	1997-02-25	Thomas Jefferson University	Mutant tumor necrosis factor proteins
US5759536A (en)	1994-05-27	1998-06-02	University Technology Corporation	Use of fas ligand to supress T-lymphocyte-mediated immune responses
WO1996003141A1 (en)	1994-07-22	1996-02-08	F. Hoffmann-La Roche Ag	Pharmaceutical compositions comprising a chimaeric tnf binding protein
GB9425060D0 (en)	1994-12-13	1995-02-08	Univ Birmingham	Carcinoma treatment
US5888764A (en) *	1995-01-20	1999-03-30	Uab Research Foundation	Human fas gene promoter region
US6017527A (en) *	1996-07-10	2000-01-25	Immunex Corporation	Activated dendritic cells and methods for their activation
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) *	1996-12-09	2006-07-04	Regents Of The University Of California	Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) *	1997-04-16	2000-01-25	Woodward Governor Company	Valve for controlling gas mass flow
EP1016721B1 (de)	1997-09-17	2010-03-10	Mochida Pharmaceutical Co., Ltd.	Fas-liganden derivate
US7786282B2 (en) *	2001-12-06	2010-08-31	The Regents Of The University Of California	Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) *	2002-05-23	2009-02-24	The Regents Of The University Of California	Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) *	2002-08-21	2005-02-16	Proimmune Ltd	Chimeric MHC protein and oligomer thereof

1997
- 1997-12-01 US US08/982,272 patent/US7070771B1/en not_active Expired - Fee Related
- 1997-12-08 AU AU57957/98A patent/AU5795798A/en not_active Abandoned
- 1997-12-08 DE DE69739220T patent/DE69739220D1/de not_active Expired - Lifetime
- 1997-12-08 BR BR9714004-0A patent/BR9714004A/pt not_active IP Right Cessation
- 1997-12-08 NZ NZ336092A patent/NZ336092A/en not_active IP Right Cessation
- 1997-12-08 AT AT09164341T patent/ATE547524T1/de active
- 1997-12-08 JP JP52695698A patent/JP4015201B2/ja not_active Expired - Fee Related
- 1997-12-08 EP EP06125424A patent/EP1806360A3/de not_active Ceased
- 1997-12-08 ES ES97954089T patent/ES2321246T3/es not_active Expired - Lifetime
- 1997-12-08 WO PCT/US1997/022740 patent/WO1998026061A2/en not_active Ceased
- 1997-12-08 IL IL13024797A patent/IL130247A0/xx active IP Right Grant
- 1997-12-08 CN CNB971816743A patent/CN1221662C/zh not_active Expired - Fee Related
- 1997-12-08 EP EP10184082A patent/EP2287309A1/de not_active Withdrawn
- 1997-12-08 AT AT97954089T patent/ATE420956T1/de not_active IP Right Cessation
- 1997-12-08 CA CA2274498A patent/CA2274498C/en not_active Expired - Fee Related
- 1997-12-08 CA CA2707726A patent/CA2707726C/en not_active Expired - Fee Related
- 1997-12-08 EP EP09164341A patent/EP2145958B1/de not_active Expired - Lifetime
- 1997-12-08 DK DK97954089T patent/DK0948614T3/da active
- 1997-12-08 EP EP97954089A patent/EP0948614B1/de not_active Expired - Lifetime
- 1997-12-08 PT PT97954089T patent/PT948614E/pt unknown
1999
- 1999-06-02 IL IL130247A patent/IL130247A/en not_active IP Right Cessation
- 1999-06-07 NO NO19992756A patent/NO327411B1/no not_active IP Right Cessation
2004
- 2004-12-17 US US11/015,117 patent/US7524944B2/en not_active Expired - Fee Related
2006
- 2006-09-26 IL IL178306A patent/IL178306A0/en not_active IP Right Cessation
2007
- 2007-09-27 NO NO20074906A patent/NO331434B1/no not_active IP Right Cessation
2009
- 2009-02-13 US US12/371,188 patent/US7906638B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69739220D1 (de)	2009-03-05
NO992756D0 (no)	1999-06-07
JP2001505782A (ja)	2001-05-08
PT948614E (pt)	2009-04-20
NO20074906L (no)	1999-08-09
US7524944B2 (en)	2009-04-28
EP2145958B1 (de)	2012-02-29
CA2274498A1 (en)	1998-06-18
WO1998026061A3 (en)	1998-11-19
CN1246892A (zh)	2000-03-08
EP0948614B1 (de)	2009-01-14
CN1221662C (zh)	2005-10-05
ES2321246T3 (es)	2009-06-03
CA2274498C (en)	2010-06-29
US7906638B2 (en)	2011-03-15
CA2707726C (en)	2013-10-22
NO992756L (no)	1999-08-09
CA2707726A1 (en)	1998-06-18
EP0948614A2 (de)	1999-10-13
WO1998026061A2 (en)	1998-06-18
IL130247A (en)	2008-03-20
NO327411B1 (no)	2009-06-22
NZ336092A (en)	2001-09-28
EP2287309A1 (de)	2011-02-23
AU5795798A (en)	1998-07-03
US20100267129A1 (en)	2010-10-21
NO331434B1 (no)	2011-12-27
US20060183199A1 (en)	2006-08-17
US7070771B1 (en)	2006-07-04
IL130247A0 (en)	2000-06-01
EP1806360A3 (de)	2007-12-12
EP1806360A2 (de)	2007-07-11
JP4015201B2 (ja)	2007-11-28
EP2145958A1 (de)	2010-01-20
DK0948614T3 (da)	2009-05-11
IL178306A0 (en)	2007-02-11
BR9714004A (pt)	2000-05-02
ATE420956T1 (de)	2009-01-15

Publication	Publication Date	Title
ATE547524T1 (de)	2012-03-15	Neuartige expressionsvektoren mit zusätzlichen molekül-ligandgenen und ihre verwendung zur immunmodulation und zur behandlung von malignomen und autoimmunkrankheiten
DE69939553D1 (de)	2008-10-23	Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
DE68913658D1 (de)	1994-04-14	Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
DE69634912D1 (de)	2005-08-11	Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
IL190793A0 (en)	2008-11-03	A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain
DE69326937D1 (de)	1999-12-09	Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
DE69329877D1 (de)	2001-02-22	Von L Protein abgeleitete Immunoglobulin-bindende Proteine und deren anwendungen
MXPA03006771A (es)	2004-05-05	Anticuerpos modificados y metodos de uso.
ATE249220T1 (de)	2003-09-15	Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
DE60237777D1 (de)	2010-11-04	Etzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
ATE374619T1 (de)	2007-10-15	Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE307886T1 (de)	2005-11-15	Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
ATE265226T1 (de)	2004-05-15	Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten
WO2001014420A3 (en)	2002-05-10	Novel members of the plexin family and uses thereof
NO20002412D0 (no)	2000-05-09	FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
DE69836758D1 (de)	2007-02-08	Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
ATE440139T1 (de)	2009-09-15	Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
DE69033810D1 (de)	2001-10-31	Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
DE59704933D1 (de)	2001-11-22	Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE60229924D1 (de)	2009-01-02	Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
DE59911733D1 (de)	2005-04-14	Verwendung von adenoassoziierten viren zur senkung der radio- oder chemotherapieinduzierten resistenz bei krebspatienten
ATE303179T1 (de)	2005-09-15	Verwendung von fluorierten triazolen zur behandlung von neuropathischem schmerz
Golen et al.	1997	Comparative estimation of local control in radiotherapy supraglottic and glottic cancer
ATE411313T1 (de)	2008-10-15	Neue makrocyclen zur behandlung von krebserkrankungen
ATE247467T1 (de)	2003-09-15	Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin